A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
- Diagnosed with HCC.
- Candidate for surgical resection or has no contraindications to MRI procedures.
- Prior loco-regional treatment of tumor, unless there is untreated tumor present
representing a distinct untreated nodule.
- Confirmed or suspected diagnosis of fibrolamellar HCC, mixed HCC/cholangiocarcinoma
or metastatic tumor.
- Had a liver transplant.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Expression levels of beta-catenin mRNA from core needle biopsy (CNB) equivalents of resected HCC.
Outcome Time Frame:
Visit 3, approximately 7 days after screening Visit 1.
United States: Institutional Review Board
- Hepatocellular Carcinoma
- hepatocellular carcinoma
- Carcinoma, Hepatocellular